Norovirus Bivalent VLP Vaccine

BIOLOGICAL2 trials

Sponsors

Takeda

Conditions

Healthy VolunteersNorovirus PreventionNorovirus, Prevention

Phase 2

Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent VLP Vaccine

CompletedNCT02038907

TakedaHealthy Volunteers, Norovirus, Prevention

Start: 2014-03-28End: 2015-06-19Updated: 2017-08-08

Safety and Immunogenicity of Norovirus Bivalent Virus-Like Particle Vaccine in Healthy Adults

CompletedNCT02142504

TakedaNorovirus Prevention

Start: 2014-05-15End: 2016-01-06Updated: 2017-08-21

Related Papers

Persistence of Antibodies to 2 Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: 1-Year Follow-up With Memory Probe Vaccination

The Journal of Infectious Diseases2019-04-0929 citations

Safety and Immunogenicity of Different Formulations of Norovirus Vaccine Candidate in Healthy Adults: A Randomized, Controlled, Double-Blind Clinical Trial

The Journal of Infectious Diseases2017-11-0672 citations

Rapid Responses to 2 Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: A Randomized Controlled Trial

The Journal of Infectious Diseases2016-06-2863 citations